Histopathologic and clinical subtypes of autoimmune pancreatitis: The honolulu consensus document

Suresh T Chari, Guenter Kloeppel, Lizhi Zhang, Kenji Notohara, Markus M. Lerch, Tooru Shimosegawa

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

Autoimmune pancreatitis (AIP) has been extensively reported from Japan, Europe, and the United States. Whereas the descriptions of AIP from Japan have predominantly been based on the presence of a distinct clinical phenotype, reports from Europe and the United States describe at least 2 histopathologic patterns in patients' condition currently diagnosed as AIP, viz, lymphoplasmacytic sclerosing pancreatitis (LPSP) and idiopathic duct centric pancreatitis (IDCP) or granulocyte epithelial lesion (GEL)-positive pancreatitis. Although the 2 entities share common histopathologic features (periductal lymphoplasmacytic infiltration and peculiar periductal fibrosis), expert pathologists can accurately distinguish them based on other unique histopathologic features. Clinically, the 2 entities have similar clinical presentation (obstructive jaundice/pancreatic mass and a dramatic response to steroids) but differ significantly in their demography, serological characteristics, other organ involvement, and disease relapse. While LPSP is associated with elevation in titers of nonspecific autoantibodies and serum IgG4 levels, IDCP does not have definitive serological autoimmune markers. All experts agreed that the clinical phenotypes associated with LPSP and IDCP should be nosologically distinguished; however, their terminology was debated. Whereas most experts agreed that the entities should be referred to as type 1 and type 2 AIP, respectively, others had concerns regarding use of the term "autoimmune" to describe IDCP.

Original languageEnglish (US)
Pages (from-to)549-554
Number of pages6
JournalPancreas
Volume39
Issue number5
DOIs
StatePublished - Jul 2010

Fingerprint

Pancreatitis
Japan
Phenotype
Obstructive Jaundice
Granulocytes
Terminology
Autoantibodies
Fibrosis
Immunoglobulin G
Steroids
Demography
Recurrence

Keywords

  • autoimmune pancreatitis
  • chronic pancreatitis
  • IgG4

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Histopathologic and clinical subtypes of autoimmune pancreatitis : The honolulu consensus document. / Chari, Suresh T; Kloeppel, Guenter; Zhang, Lizhi; Notohara, Kenji; Lerch, Markus M.; Shimosegawa, Tooru.

In: Pancreas, Vol. 39, No. 5, 07.2010, p. 549-554.

Research output: Contribution to journalArticle

Chari, Suresh T ; Kloeppel, Guenter ; Zhang, Lizhi ; Notohara, Kenji ; Lerch, Markus M. ; Shimosegawa, Tooru. / Histopathologic and clinical subtypes of autoimmune pancreatitis : The honolulu consensus document. In: Pancreas. 2010 ; Vol. 39, No. 5. pp. 549-554.
@article{c1310c6212eb468ba793a8d9b231dd73,
title = "Histopathologic and clinical subtypes of autoimmune pancreatitis: The honolulu consensus document",
abstract = "Autoimmune pancreatitis (AIP) has been extensively reported from Japan, Europe, and the United States. Whereas the descriptions of AIP from Japan have predominantly been based on the presence of a distinct clinical phenotype, reports from Europe and the United States describe at least 2 histopathologic patterns in patients' condition currently diagnosed as AIP, viz, lymphoplasmacytic sclerosing pancreatitis (LPSP) and idiopathic duct centric pancreatitis (IDCP) or granulocyte epithelial lesion (GEL)-positive pancreatitis. Although the 2 entities share common histopathologic features (periductal lymphoplasmacytic infiltration and peculiar periductal fibrosis), expert pathologists can accurately distinguish them based on other unique histopathologic features. Clinically, the 2 entities have similar clinical presentation (obstructive jaundice/pancreatic mass and a dramatic response to steroids) but differ significantly in their demography, serological characteristics, other organ involvement, and disease relapse. While LPSP is associated with elevation in titers of nonspecific autoantibodies and serum IgG4 levels, IDCP does not have definitive serological autoimmune markers. All experts agreed that the clinical phenotypes associated with LPSP and IDCP should be nosologically distinguished; however, their terminology was debated. Whereas most experts agreed that the entities should be referred to as type 1 and type 2 AIP, respectively, others had concerns regarding use of the term {"}autoimmune{"} to describe IDCP.",
keywords = "autoimmune pancreatitis, chronic pancreatitis, IgG4",
author = "Chari, {Suresh T} and Guenter Kloeppel and Lizhi Zhang and Kenji Notohara and Lerch, {Markus M.} and Tooru Shimosegawa",
year = "2010",
month = "7",
doi = "10.1097/MPA.0b013e3181e4d9e5",
language = "English (US)",
volume = "39",
pages = "549--554",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Histopathologic and clinical subtypes of autoimmune pancreatitis

T2 - The honolulu consensus document

AU - Chari, Suresh T

AU - Kloeppel, Guenter

AU - Zhang, Lizhi

AU - Notohara, Kenji

AU - Lerch, Markus M.

AU - Shimosegawa, Tooru

PY - 2010/7

Y1 - 2010/7

N2 - Autoimmune pancreatitis (AIP) has been extensively reported from Japan, Europe, and the United States. Whereas the descriptions of AIP from Japan have predominantly been based on the presence of a distinct clinical phenotype, reports from Europe and the United States describe at least 2 histopathologic patterns in patients' condition currently diagnosed as AIP, viz, lymphoplasmacytic sclerosing pancreatitis (LPSP) and idiopathic duct centric pancreatitis (IDCP) or granulocyte epithelial lesion (GEL)-positive pancreatitis. Although the 2 entities share common histopathologic features (periductal lymphoplasmacytic infiltration and peculiar periductal fibrosis), expert pathologists can accurately distinguish them based on other unique histopathologic features. Clinically, the 2 entities have similar clinical presentation (obstructive jaundice/pancreatic mass and a dramatic response to steroids) but differ significantly in their demography, serological characteristics, other organ involvement, and disease relapse. While LPSP is associated with elevation in titers of nonspecific autoantibodies and serum IgG4 levels, IDCP does not have definitive serological autoimmune markers. All experts agreed that the clinical phenotypes associated with LPSP and IDCP should be nosologically distinguished; however, their terminology was debated. Whereas most experts agreed that the entities should be referred to as type 1 and type 2 AIP, respectively, others had concerns regarding use of the term "autoimmune" to describe IDCP.

AB - Autoimmune pancreatitis (AIP) has been extensively reported from Japan, Europe, and the United States. Whereas the descriptions of AIP from Japan have predominantly been based on the presence of a distinct clinical phenotype, reports from Europe and the United States describe at least 2 histopathologic patterns in patients' condition currently diagnosed as AIP, viz, lymphoplasmacytic sclerosing pancreatitis (LPSP) and idiopathic duct centric pancreatitis (IDCP) or granulocyte epithelial lesion (GEL)-positive pancreatitis. Although the 2 entities share common histopathologic features (periductal lymphoplasmacytic infiltration and peculiar periductal fibrosis), expert pathologists can accurately distinguish them based on other unique histopathologic features. Clinically, the 2 entities have similar clinical presentation (obstructive jaundice/pancreatic mass and a dramatic response to steroids) but differ significantly in their demography, serological characteristics, other organ involvement, and disease relapse. While LPSP is associated with elevation in titers of nonspecific autoantibodies and serum IgG4 levels, IDCP does not have definitive serological autoimmune markers. All experts agreed that the clinical phenotypes associated with LPSP and IDCP should be nosologically distinguished; however, their terminology was debated. Whereas most experts agreed that the entities should be referred to as type 1 and type 2 AIP, respectively, others had concerns regarding use of the term "autoimmune" to describe IDCP.

KW - autoimmune pancreatitis

KW - chronic pancreatitis

KW - IgG4

UR - http://www.scopus.com/inward/record.url?scp=77954102252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954102252&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e3181e4d9e5

DO - 10.1097/MPA.0b013e3181e4d9e5

M3 - Article

C2 - 20562576

AN - SCOPUS:77954102252

VL - 39

SP - 549

EP - 554

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -